China Editor Karen Xi
Dear *|FNAME|*,
We are just over halfway through 2020 and while a tumultuous year for most, the biopharma world has kept its engines running. In this July edition of PharmaBoardroom's China Digest, I'd like to particularly highlight our exclusive interview with Emmanual Hanon, SVP for Vaccines R&D GSK, who discusses GSK's role in the global COVID-19 vaccine race and the importance of collaboration.
Our Biotech of the Month is the exciting young ophthalmology-focused company Arctic Vision, who recently closed a USD 32 million Series A funding round. Led by industry veterans with global and China experience, Arctic Vision is riding a wave of growing interest in the previously overlooked ophthalmology sector, which, incidentally, has been one of the top therapeutic areas for VC investment in H1 2020.
Please also take a look at the first issue in our InFocus Five Biotechs To Watch in China series, which features interviews with five of China's most promising biotechs across varying development stages: Arctic Vision, Harbour BioMed, Alphamab Oncology, I-Mab Biopharma and Zai Lab. It is available for free download below.
Please get in touch with me at karenx@focusreports.net with comments or ideas for next month's China Digest.
|
|
|
|
Dr Eddy Wu, CEO, Dr Qing Liu, VP for Clinical & Regulatory Affairs and Dr Yi (York) Chen, VP for Operations and Commercial Planning at Arctic Vision share the firm's priorities and how the company is positioning itself in relation to much larger companies in the Chinese ophthalmology market.
|
|
|
AI IN TARGET DISCOVERY
|
Alex Zhavoronkov, CEO of Insilico Medicine, lifts the lid on the role of AI in target discovery, identification, and validation. He also offers his opinion on the future of innovative drug development in China, and the challenges of establishing a biotech company in Hong Kong.
Scan or click the QR code below to download Insilico's latest report:
|
|
|
RNA STRATEGY
|
|
Dr Brett Monia, co-founder and CEO of RNA therapeutics pioneer Ionis Pharmaceuticals, outlines the company’s extremely promising development pipeline, commercial partnerships with Big Pharma, and his ambitious strategy to launch ten or more products by 2025.
|
|
|
PRECISION MEDICINE
|
Sangrae Cho – CEO, Gencurix
Gencurix was the first Asian company to develop a prognostic diagnostic test for breast cancer. Its CEO, Dr Sangrae Cho, discusses the importance of creating a test tailored to Asian patients, explores the company’s expansion plans into China, Japan, and Southeast Asia, and the synergies in their partnerships with big pharma.
|
|
|
EXCLUSIVE REPORT
|
5 Biotechs to Watch in China
This inaugural edition of the InFocus Five Biotechs To Watch in China has selected companies at different stages of the biotech journey in order to showcase the diverse and multifaceted nature of Chinese biopharma innovation.
|
|
|
VACCINE DEVELOPMENT WITH MRNA
|
GSK: Senior VP for Vaccines R&D on COVID-19 Collaboration
GSK, the world’s largest manufacturer of vaccines, has pursued a different strategy to that of its contemporaries in the effort to develop a safe, effective, and mass-producible COVID-19 vaccine. PharmaBoardroom recently spoke to Emmanuel Hanon, GSK’s senior VP for vaccines R&D, to get his take on the company’s unique role in the global vaccine race and the challenges inherent in this endeavour. Read more...
|
|
|
GLOBAL VACCINE RACE
|
CanSinoBIO: China’s Leading COVID-19 Vaccine Developer Talks Timelines
Chinese biotech CanSinoBIO is racing against the clock to have a COVID-19 vaccine ready to begin production in early 2021. The firm’s senior VP of International Business Pierre Morgon reflects on CanSinoBIO’s progress thus far and a timeline of what we can realistically expect if and when Chinese authorities give the vaccine the green light. Read more...
|
|
The Pharma Legal Handbook
|
|
|
|
|
|
|
